The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could ...

Aptadir Therapeutics, a biotech focused on RNA inhibitor therapies for cancer and genetic conditions, has launched with $1.6 ...

Aptadir Therapeutics (Aptadir), a biotech company developing RNA inhibitor-based therapeutics for treating intractable ...

What considerations can you share regarding switching patients from intravenous to oral therapies during myelodysplastic syndrome treatment, including factors such as efficacy, safety, and patient ...